Deep Dive
来自我们记者的行业洞察
Boston Scientific exits Lotus program, further consolidating the duopoly in the TAVR market
Boston Scientific recently decided to terminate its Lotus Edge transcatheter aortic valve replacement (TAVR) program and recall unused devices. This move exits it from the rapidly growing market, which will be led by Medtronic and Edwards Lifesciences for the coming years. Experts project the global TAVR market will double to approximately $10 billion by 2025.
COVID-19 Testing Hits Bottlenecks: What's Next?
Six months after the U.S. declared a public health emergency, COVID-19 testing still faces severe challenges. Despite new testing products from companies like Abbott, BD, and Roche, and increased capacity at commercial laboratories, the weekly testing capacity of 4.5 million falls far short of the 30 million target recommended by the Rockefeller Foundation. Antigen testing is seen as key to expanding screening scale, but its sensitivity gap compared to PCR testing, backlogs at commercial laboratories, and federal funding shortfalls remain unresolved issues.
Medical Device Industry Recovery: Elective Surgeries Bottom Out and Rebound, Companies Re-engage with Patients and Healthcare Providers
In the early stages of the COVID-19 pandemic, U.S. medical device companies were severely impacted by the suspension of elective surgeries, with some business segments declining by 50% to 70%. However, as surgical volumes rebounded by the end of the second quarter, industry performance exceeded expectations. Based on MedTech Dive's series of reports, this article analyzes recovery trends, regional differences, patient confidence, and opportunities in ambulatory surgery centers, citing perspectives from analysts, physicians, and industry executives.
Return-to-work testing is not a silver bullet: LabCorp and Quest push COVID-19 tests, but employers remain cautious
As U.S. states reopen their economies, testing giants like LabCorp and Quest are actively marketing return-to-work COVID-19 testing services to employers, but employers are hesitant due to concerns about accuracy, logistics, and insufficient federal guidance.
The pandemic gives rise to a highlight moment for telemedicine: where will it go in the post-COVID era?
The COVID-19 pandemic has moved telemedicine from the margins to the mainstream, with usage surging. This article analyzes its growth data, policy changes, potential obstacles, and future prospects, and points out that employers need to incorporate telemedicine into long-term human resource strategies.